As our StartEngine campaign enters its final weeks, we’re excited to invite you to a special webinar event on November 26th at 4:30 PM Eastern Time. This session offers a unique opportunity to engage directly with our CEO, Michael Marquardt, and our Chief Scientist & Founder, Dr. Fang, before our campaign closes.
Why This Webinar Matters
Early cancer detection can mean the difference between life and death. While this fact drives our work every day at Epi One, it also underscores why this webinar is so important. We’ll share how our technology aims to detect cancer earlier, when treatment options are most effective and outcomes are better.
Our approach to cancer detection combines epigenetics with practical diagnostic tools – but what does this mean for patients, doctors, and the future of cancer screening? During this webinar, Michael will break down the science behind our work and explain how we’re working to make cancer screening more accessible and affordable.
What to Expect
This isn’t just another corporate presentation. We’ve structured this session to be interactive and informative, focusing on the questions that matter most to our community of supporters and potential investors. Here’s what we’ll cover:
- Technical Innovation: A clear explanation of our detection method and how it works
- Market Impact: Understanding where we fit in the current healthcare landscape
- Development Progress: Our timeline, achievements, and next steps
- Open Q&A: Your chance to ask questions directly to our CEO
Meet Our Speakers
Michael Marquardt brings unique insight to this conversation. As the former Board Chair of the American Cancer Society and our current CEO, he bridges the gap between understanding cancer’s impact on society and leading technological innovation in cancer detection. With his background in chemistry and extensive experience in both healthcare and technology sectors, Michael offers a comprehensive perspective on our work and its potential impact.
Dr. Fang “Sophia” Fang brings extensive expertise in genomics and cancer biology as Epi One’s Co-Founder and Chief Scientific Officer. With both an MD and PhD, her research at Memorial Sloan Kettering Cancer Center focused on identifying cancer biomarkers and understanding tumor progression. Dr. Fang’s dual degrees from Harbin Medical University and Iowa State University combine clinical knowledge with advanced research capabilities, enabling her to bridge the gap between laboratory innovation and practical medical applications in Epi One’s early detection technology.
Why Attend?
Whether you’re a current investor, considering an investment, or simply interested in cancer detection technology, this webinar offers valuable insights. You’ll learn:
- How our technology differs from current cancer screening methods
- The specific challenges we’re addressing in cancer detection
- Our progress and key milestones
- Where we’re headed and how we plan to get there
Making an Informed Decision
With our StartEngine campaign closing soon, this webinar serves as your final opportunity to gather the information you need to make an informed investment decision. We believe in transparency and want to ensure you have all the facts about our work, our goals, and our vision for the future.
Join Us
Don’t miss this opportunity to be part of our journey to improve cancer detection. Register now for our webinar on November 26th at 4:30 PM Eastern Time. Bring your questions, your curiosity, and your passion for advancing healthcare.
Register here: https://dnagency.lpages.co/epi-one-final-investor-webinar/
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
